Biodesix, Inc. (BDSX) Stock

Biodesix, Inc. (BDSX) is a Healthcare stock trading at $17.00 (as of 2026-06-18), with a market capitalization of $162.75M and a trailing P/E of -2.8. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Biodesix, Inc. provides blood-based diagnostic testing focused on lung cancer risk assessment and molecular characterization, including Nodify XL2 and Nodify CDT, as well as GeneStrat ddPCR and VeriStrat, and a 72-hour GeneStrat NGS test. It also offers COVID-19 testing through its WorkSafe program with Bio-Rad, and provides diagnostic and clinical research and clinical trial testing services.

Valuation — source: SEC EDGAR (first-party)
Price	$17.00
Market Cap	$162.75M
P/E Ratio	-2.8
EV / EBITDA	-9.1
Price / Book	16.67
Price / Sales	1.58
DCF Value (model)	$-43.77
DCF Upside vs Price	-357.5%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$88.50M
Net Margin	-39.8%
Return on Equity	-349.9%
Debt / Equity	5.48
Current Ratio	2.82
Revenue Growth (YoY)	24.1%
EPS Growth (YoY)	1315.2%
FCF Growth (YoY)	-54.6%

Financial Health — source: SEC EDGAR
Altman Z-Score	-6.68 (distress)

Valuation vs Sector & Industry
Stock P/E	-2.8
Sector P/E (Healthcare)	21.0
Industry P/E (Healthcare Services)	23.0
vs Sector	-113.3%
vs Industry	-112.1%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	AIGH Capital Management LLC ($11.00M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Healthcare Services
CEO	Scott Hutton
Employees	273
Country	US
IPO Date	2020-10-28

Related Companies (Business model: Clinical Labs / CRO Services; 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.